

Research Transparency in 59 Fields of Medical and Health Sciences: A Meta-Research Study

Ahmad Sofi-Mahmudi*¹⁻³, ORCID: 0000-0001-6829-0823

Eero Raittio^{4,5}, ORCID: 0000-0002-9258-9355

Sergio E. Uribe⁶⁻⁸, ORCID: 0000-0003-0684-2025

Sahar Khademioore², ORCID: 0000-0002-3025-0006

Dena Zeraatkar^{1,2}, ORCID: 0000-0003-4287-0541

Lawrence Mbuagbaw^{1,2,9-11}, ORCID: 0000-0001-5855-5461

Lex M. Bouter^{12,13}, ORCID: 0000-0002-2659-5482

Karen A. Robinson^{14,15}, ORCID: 0000-0003-1021-7820

1 National Pain Centre, Department of Anesthesia, McMaster University, Hamilton, ON, Canada.

2 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.

3 Seqiz Health Network, Kurdistan University of Medical Sciences, Seqiz, Kurdistan.

4 Institute of Dentistry, University of Eastern Finland, Kuopio, Finland.

5 Department of Dentistry and Oral Health, Aarhus University, Aarhus, Denmark.

6 Department of Conservative Dentistry and Oral Health, Riga Stradins University, Riga, Latvia.

7 Faculty of Dentistry, Universidad de Valparaíso, Valparaíso, Chile.

8 Baltic Biomaterials Centre of Excellence, Headquarters at Riga Technical University, Riga, Latvia.

9 Biostatistics Unit, Father Sean O'Sullivan Research Centre, Hamilton, ON, Canada.

10 Centre for Development of Best Practices in Health, Yaoundé Central Hospital, Yaoundé, Cameroon.

11 Department of Global Health, Stellenbosch University, Cape Town, South Africa.

12 Amsterdam University Medical Center, Amsterdam, the Netherlands.

13 Vrije Universiteit, Amsterdam, the Netherlands.

14 Johns Hopkins University School of Medicine, Department of Medicine, Baltimore, MD, USA.

15 Section for Evidence-Based Practice, Western Norway University of Applied Sciences, Bergen, Norway.

29 **Corresponding author:** Ahmad Sofi-Mahmudi; **Address:** MDCL-2109, 1280 Main Street West,
30 Hamilton, ON L8S 4K1, Canada; **Telephone:** +1 (905) 525-9140 ext. 22743; **Email:**
31 sofima@mcmaster.ca; a.sofimahmudi@gmail.com.

32

33 **Conflict of interest disclosure:** The authors have no conflicts of interest to disclose.

34

35 **Funding disclosure:** This study did not receive any funding.

36

37 **Acknowledgments:** The computational analyses were performed on servers provided by UEF
38 Bioinformatics Center, University of Eastern Finland, Finland. Uribe was supported by the European
39 Union's Horizon 2020 grant 857287 for the Baltic Biomaterials Centre of Excellence, Headquarters at
40 Riga Technical University, Riga, Latvia.

41 **Abstract**

42 **Background:** Transparency in research is crucial as it allows for the scrutiny and replication of
43 findings, fosters confidence in scientific outcomes, and ultimately contributes to the advancement of
44 knowledge and the betterment of society.

45 **Aim:** We aimed to assess adherence to five practices promoting transparency in scientific publications
46 (data availability, code availability, protocol registration, conflicts of interest (COI) and funding
47 disclosures) from open-access articles published in medical journals.

48 **Methods:** We searched and exported all open-access articles from Science Citation Index Expanded
49 (SCIE)-indexed journals through the Europe PubMed Central database published until March 16, 2024.
50 Basic journal- and article-related information was retrieved from the database. We used R to produce
51 descriptive statistics.

52 **Results:** The analysis included 2,189,542 open-access articles from SCIE-indexed medical journals. Of
53 these, 87.5% (95% CI: 87.4%-87.5%) disclosed COI and 80.1% (95% CI: 80.0%-80.1%) disclosed
54 funding. Protocol registration was present in 6.6% (95% CI: 6.6%-6.6%), data sharing in 7.6% (95%
55 CI: 7.6%-7.6%), and code sharing in 1.4% (95% CI: 1.4%-1.4%) of the articles. More than 76.0%
56 adhered to at least two transparency practices, while full adherence to all five practices was less than
57 0.02%. The data showed an increasing trend in adherence to transparency practices since the late
58 2000s. COI and funding were disclosed more often in lower impact factor journals whereas protocol
59 registration and data and code sharing were more prevalent in higher impact factor journals (all had P-
60 values<0.001). Also, articles that did not disclose their COI had higher median citations. Among all
61 fields, Rheumatology (97.2%), Neuroimaging (94.6%), Anesthesiology (32.4%), Genetics & Heredity
62 (36.7%), and Neuroimaging (12.5%) showed the highest level of transparency in COI and funding
63 disclosure, protocol registration, and data and code sharing, respectively. Whereas Medicine, Legal
64 (61.5%), Andrology (59.0%), Materials Science, Biomaterials (0.3%), Surgery (1.5%), and Nursing
65 (<0.01%) showed the lowest adherence.

66 **Conclusion:** While most articles and fields had a COI disclosure, adherence to other transparent
67 practices was far from acceptable. To increase protocol registration, data, and code sharing, much
68 stronger commitment is needed from all stakeholders.

69 *Keywords:* Conflict of Interest; Code Sharing, Data Sharing; Funding Disclosure, Information
70 Dissemination, Meta-research, Open Science, Protocol Registration.

71 **Background**

72 Recent recognition of health research transparency, essential for accountability, has resulted in
73 stringent disclosure requirements by academic, medical institutions, and voluntary industry and
74 publisher codes (1,2). Although global regulatory bodies, funding agencies, and ethics boards supervise
75 medical research, transparency and disclosure practices are still inconsistent and incomplete (3,4).
76 Research conducted by industry, academia, or their collaboration equally has deficiencies in
77 transparency (2,5). Despite publishers' policies, ethical mandates, and mission statements (6), academic
78 medical centers show poor performance and significant variation in disseminating clinical trial results
79 following transparency practices (7). Transparency in research is pivotal for accountability and trust in
80 results and upholds the ethical responsibilities of researchers, editors, publishers, and funders (8–12).
81 Inefficient use of primarily public or non-profit research funding significantly disadvantages patients
82 and society.

83 Key indicators of research transparency include data sharing, code sharing, disclosures of conflicts of
84 interest, funding acknowledgments, and protocol registration (13). Data sharing is more common in
85 non-COVID-19 articles (12%) than in COVID-19 studies (4%) (14). A systematic review of 105 meta-
86 research studies, analyzing 2,121,580 articles across 31 specialties, uncovered substantial transparency
87 challenges (15). Issues include low declared (8%) and actual (2%) public data availability, minimal
88 public code sharing (<0.5%), and inconsistent journal data-sharing policy adherence. The review also
89 noted discrepancies between declared and actual data sharing practices and challenges in privately
90 obtaining data and code from authors (15). These findings highlight the pressing need to enhance
91 transparency, particularly during public health crises.

92 Our meta-research study assessed research transparency regarding data and code sharing, conflict of
93 interest (COI) and funding disclosure, and protocol registration across all medical specialties. Through
94 programmatic and comprehensive analysis, we aimed to identify patterns and areas most needing
95 improvement.

96

97 **Methods**

98 The protocol of this descriptive study was published on the Open Science Framework (OSF) website
99 (<https://doi.org/10.17605/OSF.IO/J57BG>). All the code and data associated with the study were shared
100 through both its OSF repository (<https://osf.io/zbc6p/>) and GitHub ([https://github.com/choxos/medical-](https://github.com/choxos/medical-transparency)
101 [transparency](https://github.com/choxos/medical-transparency)). To ensure transparency and facilitate the reproducibility of our analyses, a PDF
102 document containing the codes and corresponding outputs is provided in Appendix 1.

103 **Data sources and study selection**

104 Initially, we searched records within journals listed in the 59 fields of the “Clinical Medicine” section
105 in the Science Citation Index Expanded (SCIE) version 2020. This search was performed using the
106 Europe PubMed Central (EPMC) database until February 28, 2022. We updated the search on March
107 16, 2024. The EPMC database encompasses all records found in PubMed and PubMed Central records
108 and allows automated retrieval of full-texts of EPMC open-access records. Remarkably, what is being
109 called “EPMC open-access articles” do not include all “open-access” labeled articles (e.g., by the
110 journals/publishers) because some of those articles are still subject to traditional copyright restrictions.
111 Thus, their full texts cannot be accessed via EPMC.

112 Using the *metareadr* package (16), we retrieved the full texts of all identified open-access records in
113 XML format from the EPMC database. Concurrently, we extracted descriptive details for each journal
114 and article, including publisher, publication year, and citations linked to the article and journal, directly
115 from the EPMC database. We categorized articles using the EPMC variable “publication type”.

116 **Data extraction and synthesis**

117 We used the *rtransparent* package (17), a validated and automated programmatic tool (13), to identify
118 five transparent practices from the full texts we were able to download from EPMC:

- 119 1. *Data sharing*: The accessibility of data or metadata obtained during a research study, typically
120 through public repositories or inclusion as supplementary materials accompanying the
121 published work.
- 122 2. *Code sharing*: The disclosure of computer code or scripts employed for data analysis in
123 research facilitates the replication of results and enables the broader utilization of the study's
124 methodologies.
- 125 3. *Conflict of interest (COI) disclosures*: The public acknowledgment of potential conflicts of
126 interest that could impact the research, commonly presented within a designated publication
127 section.
- 128 4. *Funding disclosures*: The disclosure of the sources of financial support for the research,
129 promoting transparency regarding the possible influence of funding organizations.
- 130 5. *Protocol registration*: The public disclosure of research protocols before conducting a study
131 designed to reduce bias and increase transparency in the research process.

132 The package uses a standardized vocabulary to identify transparency indicators in EPMC XML files. It
133 detects keywords related to COI disclosure, such as “conflicts of interest,” “competing interests,” or
134 “nothing to disclose,” in article section titles or bodies. The tool recognizes all mentions of COI and
135 funding disclosures and treats “nothing to disclose” statements as an indication of transparency, similar
136 to actual conflict disclosures.

137 To assess data and code sharing, the *rtransparent* tool detects materials that are shared either as
138 supplemental content, in general repositories (e.g., figshare, OSF, GitHub), or in field-specific
139 repositories (e.g., dbSNP, ProteomeXchange, GenomeRNAi). Items that state “data available upon
140 request” are not considered data sharing due to the unlikelihood of data acquisition (18). The
141 *rtransparent* tool demonstrates robust validation, with high sensitivity and specificity for detecting
142 transparency indicators: conflict of interest disclosure (sensitivity 99.2%, specificity 99.5%), funding
143 disclosure (sensitivity 99.7%, specificity 98.1%), protocol registration (sensitivity 95.5%, specificity
144 99.7%), data sharing (sensitivity 75.8%, specificity 98.6%), and code sharing (sensitivity 58.7%,
145 specificity 99.7%) (13).

146 **Data analysis**

147 First, we computed the percentage of articles with full-texts available via EPMC (EPMC open-access
148 records) out of the total number of articles within the database. Alongside providing descriptive
149 statistics for the obtained sample, we reported adherence to transparency practices categorized by
150 publication type. We also determined and reported the number of transparency practices that articles
151 with available full-text adhered to within each publication type, ranging from 0 to 5 practices.
152 Furthermore, we charted differences in transparency practices between 59 distinct fields over time. The
153 sensitivity and specificity of the *rtransparent* tool (17) were used to generate 95% confidence intervals

154 (CIs) for the estimates of the transparency practices. We used visual presentation and Pearson's
155 product-moment correlation to analyze the yearly adherence trend to transparency practices. We used
156 the Wilcoxon rank-sum test to test the statistical significance of the relationship between transparency
157 indicators and journal impact factor or received citations. We also used a random intercept generalized
158 linear model to investigate the trend of adherence to transparency practices among different fields.

159

160 **Results**

161 **General characteristics**

162 As of March 16, 2024, EPMC contained 17,694,287 articles. Of which, 2,189,542 (12.4%) records had
163 full text available for download. Of those, 41,335 were published before 2000, 894,500 in the 2010s,
164 and 1,157,514 after 2020. The articles came from 3,475 journals, led by the International Journal of
165 Environmental Research and Public Health (n=61,041), Medicine (Baltimore) (n=35,6825), and
166 Frontiers in Immunology (n=34,181).

167 **Field-specific characteristics**


168 On average, 89.6% (SD=8.82%) of the journals had at least one downloadable full-text in EPMC
169 (Appendix 2). For full-text availability in EPMC, Tropical Medicine (39.8%, n=34,032), Medicine,
170 Research & Experimental (33.2%, n=186,337), and Medicine, General & Internal (31.6%, n=233,385)
171 led, while Audiology & Speech-Language Pathology (2.6%, 1,646 articles), Transplantation (3.3%,
172 4,987 articles), and Medicine, Legal (3.5%, 1,417 articles) had the lowest availability. See Appendix 2
173 for details.

174 **Overall adherence to transparency practices**

175 Of the analyzed full-text articles, 87.5% (95% CI: 87.4%-87.5%) disclosed a COI. Funding disclosures
176 were present in 80.1% (95% CI: 80.0%-80.1%) of articles. Pre-publication registration occurred in
177 6.6% (95% CI: 6.6%-6.6%) and data sharing in 7.6% (95% CI: 7.6%-7.6%) of articles. Code sharing
178 occurred in 1.4% (95% CI: 1.4%-1.4%). More than 76.0% complied with at least two transparency
179 indicators, while less than 0.02% complied with all five.

180 Figure 1A shows the overall adherence to each transparency indicator. A visual analysis of the data
181 since the end of the 2000s shows a steady increase in the proportion of articles that adhere to
182 transparency practices (Figure 1B). Pearson's product-moment correlation between publication year
183 and adherence to transparency practices was highest for funding disclosure (0.716) and lowest for code
184 sharing (0.521). All the *P*-values were <0.001 (Appendix 1).

185



186

187 **Figure 1.** The proportion of 2,189,542 analyzed articles that adhered to transparency practices in total
188 (A) and over time (B, in log scale).

189

190 COI and funding were disclosed more often in lower impact factor journals whereas protocol
191 registration and data and code sharing were more prevalent in higher impact factor journals (all had P -
192 values<0.001). Also, articles that did not disclose their COI had higher median citations (Table 1).

193

194 **Table 1.** Associations of transparency practices with citations of articles and journal impact factor

Transparency practice	Citations to article			Journal impact factor		
	Median (IQR)		P	Median (IQR)		P
	Adhered to	Did not adhere to		Adhered to	Did not adhere to	
COI disclosure	2 (7)	7 (18)	<0.001	3.932 (2.782)	3.696 (5.011)	<0.001
Funding disclosure	2 (8)	3 (10)	<0.001	3.989 (2.833)	3.500 (3.295)	<0.001
Protocol registration	2 (6)	3 (9)	<0.001	3.394 (2.766)	3.969 (2.921)	<0.001
Data sharing	3 (9)	2 (9)	<0.001	4.546 (3.124)	3.835 (2.974)	<0.001
Code sharing	2 (6)	2 (9)	<0.001	4.615 (2.998)	3.921 (2.963)	<0.001

195

196

197 **Transparency practices by fields**

198 *Conflict of Interest Disclosure*

199 Rheumatology, with a 97.2% rate of COI disclosures, leads alongside Primary Health Care (96.4%) and
200 Nutrition & Dietetics (95.8%). On the lower end, Medicine, Legal shows 61.5%, Toxicology 66.4%,
201 and Neuroimaging 71.2% (Appendix 3). The 2010s marked a period of increasing COI disclosures
202 across most fields (Appendix 4).

203 ***Funding Disclosure***

204 The highest rates of funding disclosure are found in Neuroimaging (94.6%), Materials Science,
205 Biomaterials (93.9%), and Audiology & Speech-language Pathology (92.6%). In contrast, Andrology
206 reports 59.0%, Medical Laboratory Technology 59.5%, and Emergency Medicine 62.9% (Appendix 3).
207 Funding disclosures, akin to COI disclosures, have shown an overall increase during the 2010s across
208 various fields (Appendix 4).

209 ***Protocol Registration***

210 Anesthesiology (32.4%) leads in protocol registration, followed by Rehabilitation (16.5%) and
211 Rheumatology (14.1%), higher than Materials Science, Biomaterials (0.3%), Genetics & Heredity
212 (0.9%), and Medical Laboratory Technology (1.0%) (Appendix 3). Anesthesiology, for example, has
213 seen a steady increase, reaching up to 40%, contrasting with consistently low rates in fields like
214 Immunology and Toxicology (Appendix 4).

215 ***Data Sharing***

216 Leading in data sharing are Genetics & Heredity (36.7%), Neuroimaging (24.5%), and Virology
217 (22.9%), while Surgery (1.5%), Orthopedics (1.5%), and Primary Health Care (1.6%) show the lowest
218 rates (Appendix 3). Although there has been an increase in data sharing in certain fields, such as
219 Neuroimaging (approximately 80% in 2022), these trends are lower compared to COI and funding
220 disclosures (Appendix 4).

221 ***Code Sharing***

222 In code sharing, Neuroimaging (12.5%), Genetics & Heredity (7.5%), and Medical Informatics (6.3%)
223 report the highest rates, in contrast to negligible rates in Nursing, Dermatology, and Integrative &

224 Complementary Medicine (Appendix 3). Code sharing remains relatively low compared to the higher
225 prevalence of COI and funding disclosures, though an increasing trend is observed in specific fields
226 (Appendix 4).

227 The random intercept generalized linear mixed-effects logistic models examining transparency
228 indicators over time among different fields showed the highest random effects variance for code
229 sharing (1.347) and the lowest for funding disclosure (0.345). Full details are available in Appendix 1
230 and 5.

231

232 **Discussion**

233 Our analyses of over two million full-text articles published in SCIE-indexed journals revealed high
234 compliance with COI and funding disclosure in medical research since the early 2010s. However, data
235 sharing, protocol registration, and code sharing remained low. A recent study highlights the critical role
236 of best practices, such as pre-registration, in research (19). It demonstrates that adherence to these
237 practices correlates with an 86% success rate in replication studies, significantly higher than the 50%
238 success rate observed in some earlier replication efforts. Given the observed low rates of protocol
239 registration, code sharing, and data sharing in our analysis, it is plausible that current research in these
240 fields may face challenges in replicability, potentially falling short of the higher success rates
241 associated with rigorous adherence to best practices.

242 To our knowledge, differences in transparency practices across a wide range of medical fields have not
243 been studied before in this level of detail. Instead of focusing on a single transparency practice, such as
244 data sharing, within one field of medicine or, e.g., its few highest-impact journals, the applied

245 programmatic approach allowed us to estimate adherence to five transparency practices across a high
246 number of studies across the range of medical fields (15). Previous research on data and code sharing
247 has often taken a more generalized approach, focusing on overarching trends within the biomedical
248 literature or narrowing their scope to specific fields or even individual journals (15). In contrast, our
249 study delved into a detailed analysis, revealing substantial disparities, particularly in protocol
250 registration and data or code sharing. These discrepancies likely mirror variations in research
251 methodologies, reporting standards, publishing norms, peer review processes, and editorial practices
252 prevalent across different medical domains. Conversely, our study indicates that COI and funding
253 disclosures have been relatively prevalent since the mid-2000s. This suggests that achieving a high
254 level of adherence to transparency practices could be attainable with concerted and universally applied
255 efforts that have been behind promoting COI and funding disclosures (20). For instance, journals could
256 adhere to Transparency and Openness Promotion Guidelines and guide authors accordingly (21).
257 Recently, it was shown that it is possible to increase adherence to data and code sharing with such
258 efforts, and thus subsequently increase the reproducibility of research substantially (22).

259 Even though we were able to use a large sample of articles and validated methods to estimate the
260 prevalence of five transparency practices, our study also has some limitations. The analyzed articles
261 represent, to some extent, a biased subset of all medical literature, even though earlier research has
262 shown that there are no clear differences in these five transparency practices between articles with and
263 without available full text in the EPMC (23). The applied methodology has not been validated for the
264 whole time, the original validation covered the years 2015-2019 (13). We cannot be sure that it is
265 equally valid/accurate within each of the 59 fields, because there may be some systematically different
266 ways of registering protocols and sharing data or code, e.g. via some smaller and thus (uncoded)
267 repositories/platforms. Furthermore, we did not manually evaluate the validity or accuracy of the

268 disclosures, protocols, or data/code availability statements, but other studies have found similar results:
269 these are frequently suboptimal (24,25). The articles in our sample included a wide range of research,
270 some of which may not have necessitated using any data or code. Consequently, we acknowledge that
271 achieving a 100% adherence rate in data and code sharing would not be a realistic expectation. For
272 instance, fields such as "Medical Ethics" or "Medicine, Legal" may predominantly comprise qualitative
273 research papers, which may not inherently involve creating or utilizing datasets or codes. Instead, in
274 fields like "Genetics & Heredity" data-intensive research is likely more common. Additionally, the
275 issue of protocol registration introduces some complexity because there is no consensus regarding the
276 necessity of pre-registration for certain study types, such as explorative (as opposed to hypothesis-
277 testing) or qualitative research. These discrepancies likely drive the observed variations across the 59
278 distinct fields. Consequently, it is essential to interpret the results with caution and make comparisons
279 with an understanding of these inherent variations across the diverse spectrum of medical research.

280 Compared to all articles with available full-text in the EPMC database (13), the analyzed subsample of
281 articles from SCIE-indexed journals showed higher adherence to COI and funding disclosures and
282 protocol registration, but equal adherence to data and code-sharing. It seems these disparities primarily
283 stem from historical trends. Specifically, the SCIE-indexed articles exhibited higher levels of
284 compliance with these practices in earlier years. Interestingly, a shift in adherence patterns becomes
285 apparent when we examine articles from the 2020s. In 2020, the sample comprising all articles with
286 available full-text in the EPMC database demonstrated greater adherence to data and code sharing, but
287 lower adherence to protocol registration, COI disclosures, and funding disclosures when compared to
288 our findings of the SCIE-indexed articles in 2022 (in parenthesis): 15% (9%) for data sharing, 3% (2%)
289 for code sharing, 90% (84.0%) for COI disclosures, 85% (77.1%) for funding disclosures, and 5% (9%)
290 for protocol registration. Menke et al. have investigated the presence of protocols and data and code

291 sharing in all articles with full-text in the EPMC database with another automated tool (26). They
292 found a similar constant trend in code-sharing adherence than we did. However, they found a more
293 pronounced increase in and higher adherence to protocol registration (19%) and data sharing (17%) in
294 2020 than our findings (9% and 9%) indicate, potentially attributable to differences in these automated
295 methods.

296 In conclusion, our study reveals that key transparency practices such as data sharing, protocol
297 registration, and especially code sharing continue to be notably scarce in medical research. While
298 adherence to COI and funding disclosures is commendable, the limited adoption of these crucial
299 practices across diverse medical fields remains a significant concern. The recent findings highlighting a
300 high replication success rate with rigorous transparency, underscore the vital need for the universal
301 adoption of such practices (19,22). We urge researchers, journal editors, and policymakers to advance
302 these practices by advocating for the standardization of protocol registration and open data/code
303 sharing across all medical fields. Such a collective commitment is essential to enhance the integrity,
304 reliability, and impact of medical research, ultimately benefiting the global health community.

305

306 **References**

- 307 1. ICMJE. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work
308 in Medical Journals [Internet]. International Committee of Medical Journal Editors (ICMJE); 2023.
309 Available from: <https://www.icmje.org/icmje-recommendations.pdf>
- 310 2. Steinbrook R, Ross JS. “Transparency Reports” on Industry Payments to Physicians and Teaching
311 Hospitals. *JAMA*. 2012 Mar 14;307(10):1029.
- 312 3. Tafuri G, Trotta F, Leufkens HGM, Pani L. Disclosure of grounds of European withdrawn and
313 refused applications: a step forward on regulatory transparency: Letter to the Editors. *Br J Clin
314 Pharmacol*. 2013 Apr;75(4):1149–51.
- 315 4. Darrow JJ, Sarpatwari A, Avorn J, Kesselheim AS. Practical, Legal, and Ethical Issues in
316 Expanded Access to Investigational Drugs. Hamel MB, editor. *N Engl J Med*. 2015 Jan

- 317 15;372(3):279–86.
- 318 5. Collier R. Transparency poor in academic medical research. *Can Med Assoc J*. 2016 May
- 319 17;188(8):E133–E133.
- 320 6. Dal-Ré R. Are the Most Prestigious Medical Journals Transparent Enough? *Trends Pharmacol Sci*.
- 321 2016 Sep;37(9):731–3.
- 322 7. Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, et al. Publication and reporting of
- 323 clinical trial results: cross sectional analysis across academic medical centers. *BMJ*. 2016 Feb
- 324 17;i637.
- 325 8. Needleman I, Moher D, Altman DG, Schulz KF, Moles DR, Worthington H. Improving the Clarity
- 326 and Transparency of Reporting Health Research: a Shared Obligation and Responsibility. *J Dent*
- 327 *Res*. 2008 Oct;87(10):894–5.
- 328 9. Nicholls SG, Langan SM, Benchimol EI, Moher D. Reporting transparency: making the ethical
- 329 mandate explicit. *BMC Med*. 2016 Dec;14(1):44, s12916-016-0587–5.
- 330 10. Munafò MR, Nosek BA, Bishop DVM, Button KS, Chambers CD, Percie du Sert N, et al. A
- 331 manifesto for reproducible science. *Nat Hum Behav* [Internet]. 2017 Jan;1(1). Available from:
- 332 <http://dx.doi.org/10.1038/s41562-016-0021>
- 333 11. Besançon L, Peiffer-Smadja N, Segalas C, Jiang H, Masuzzo P, Smout C, et al. Open science saves
- 334 lives: lessons from the COVID-19 pandemic. *BMC Med Res Methodol* [Internet]. 2021 Jun
- 335 5;21(1). Available from: <http://dx.doi.org/10.1186/s12874-021-01304-y>
- 336 12. Bosma CM, Granger AM. Sharing is caring: Ethical implications of transparent research in
- 337 psychology. *Am Psychol*. 2022 May;77(4):565–75.
- 338 13. Serghiou S, Contopoulos-Ioannidis DG, Boyack KW, Riedel N, Wallach JD, Ioannidis JPA.
- 339 Assessment of transparency indicators across the biomedical literature: How open is open? Bero L,
- 340 editor. *PLOS Biol*. 2021 Mar 1;19(3):e3001107.
- 341 14. Zavalis EA, Contopoulos-Ioannidis DG, Ioannidis JPA. Transparency in Infectious Disease
- 342 Research: Meta-research Survey of Specialty Journals. *J Infect Dis*. 2023 Aug 11;228(3):227–34.
- 343 15. Hamilton DG, Hong K, Fraser H, Rowhani-Farid A, Fidler F, Page MJ. Prevalence and predictors
- 344 of data and code sharing in the medical and health sciences: systematic review with meta-analysis
- 345 of individual participant data. *BMJ*. 2023 Jul 11;e075767.
- 346 16. Serghiou S. Metareadr: Downloads data often needed for meta-research [Internet]. 2022. Available
- 347 from: <https://github.com/serghiou/metareadr>
- 348 17. Serghiou S. rtransparent: Identifies indicators of transparency. 2021; Available from:
- 349 <http://github.com/serghiou/rtransparent>
- 350 18. Gabelica M, Bojčić R, Puljak L. Many researchers were not compliant with their published data
- 351 sharing statement: a mixed-methods study. *J Clin Epidemiol*. 2022 Oct;150:33–41.
- 352 19. Protzko J, Krosnick J, Nelson L, Nosek BA, Axt J, Berent M, et al. High replicability of newly
- 353 discovered social-behavioural findings is achievable. *Nat Hum Behav* [Internet]. 2023 Nov 9 [cited
- 354 2023 Dec 9]; Available from: <https://www.nature.com/articles/s41562-023-01749-9>
- 355 20. Lo B, Field MJ, Institute of Medicine (U.S.), editors. Conflict of interest in medical research,
- 356 education, and practice. Washington, D.C: National Academies Press; 2009. 414 p.
- 357 21. Nosek BA, Alter G, Banks GC, Borsboom D, Bowman S, Breckler S, et al. Transparency and
- 358 openness promotion (TOP) guidelines. 2016;
- 359 22. Fišar M, Greiner B, Huber C, Katok E, Ozkes A, Collaboration MSR. Reproducibility in
- 360 Management Science [Internet]. Open Science Framework; 2023 Nov [cited 2023 Dec 9].
- 361 Available from: <https://osf.io/mydzv>
- 362 23. Wallach JD, Boyack KW, Ioannidis JPA. Reproducible research practices, transparency, and open

- 363 access data in the biomedical literature, 2015–2017. Dirnagl U, editor. *PLOS Biol.* 2018 Nov
364 20;16(11):e2006930.
- 365 24. Page MJ, Nguyen PY, Hamilton DG, Haddaway NR, Kanukula R, Moher D, et al. Data and code
366 availability statements in systematic reviews of interventions were often missing or inaccurate: a
367 content analysis. *J Clin Epidemiol.* 2022 Jul;147:1–10.
- 368 25. Dunn AG, Coiera E, Mandl KD, Bourgeois FT. Conflict of interest disclosure in biomedical
369 research: a review of current practices, biases, and the role of public registries in improving
370 transparency. *Res Integr Peer Rev.* 2016 Dec;1(1):1.
- 371 26. Menke J, Roelandse M, Ozyurt B, Martone M, Bandrowski A. The Rigor and Transparency Index
372 Quality Metric for Assessing Biological and Medical Science Methods. *iScience.* 2020
373 Nov;23(11):101698.

